MacroGenics, Inc.

NASDAQ:MGNX

Biotechnology

Healthcare
$1.97 +2.02%

+$0.08 today

Market cap
$125.90M
Beta
1.20
P/E (TTM)
-3.6
EPS (TTM)
-$1.11
52W Low $1.19High $4.64

Volume 0.72M

Average 0.98M

MGNX Other Income / Expenses

Net non-operating gains and losses, such as investment results, currency effects, and one-off items.

MacroGenics, Inc.NASDAQ: MGNX

Other Income / Expenses · Q1 FY2026 · quarter ended Mar 2026

Other income / expenses turns negative

Q1 FY2026 other income / expenses was -$3.34M, compared with $1.59M a year earlier. Trailing-twelve-month other income / expenses was -$7.37M.

Context

  • Other income / expenses amounted to 1.6% of revenue in FY2025, down 28.4 pp from a year earlier.
  • Other income / expenses increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly other income / expenses holds near -$3.34M or moves back toward the trailing-twelve-month quarterly average of -$1.84M.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$3.34M-17.6% QoQ
Last fiscal yearDec 2025
-$2.45M-105.5% YoY
LTMMar 2026
-$7.37M-116.5% YoY
Other Income / Expenses past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-310.0%——
1 year-105.5%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Other Income / Expenses history

USD · from the income statement

Latest · FY2025
(2.45M) USD
Year-over-year change
-105.5%

Other Income / Expenses vs competitors

How MGNX compares with its peers on the latest reported figures

  • Peers report in different currencies, so other income / expenses is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -116.5% is the 10th highest of 11, against a peer median of -40.2%.
  • Other income / expenses amounts to 4.7% of revenue for MGNX, versus a peer median of 915.8%.
MGNX Competitors
Other Income / Expenses for MGNX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ORMPOramed Pharmaceuticals Inc.LTM Mar 2026$146.07M USD+1533.0%+213.5%—
OVIDOvid Therapeutics Inc.LTM Mar 2026$23.57M USD-26.4%+162.8%330.9%
ZNTLZentalis Pharmaceuticals, Inc.LTM Mar 2026$21.47M USD+277.4%——
WHWKWhitehawk Therapeutics IncLTM Mar 2026$6.9M USD-92.4%+251.1%—
CNTXContext Therapeutics Inc.LTM Mar 2026$3.29M USD-17.6%+87.2%—
CNTBConnect Biopharma Holdings LimitedFY2025$2.79M USD-60.4%+22.4%4360.9%
STTKShattuck Labs, Inc.LTM Mar 2026$2.79M USD-35.2%+24.9%279.0%
COYACoya Therapeutics, Inc.LTM Mar 2026$869.27K USD-45.2%—10.9%
IFRXInflaRx N.V.LTM Mar 2026-€440.14K EUR-104.4%-1.4%1500.6%
MGNXMacroGenics, Inc.LTM Mar 2026-$7.37M USD-116.5%—4.7%
CLNNClene Inc.LTM Mar 2026-$12.7M USD-1019.6%—9474.6%
Peer median (excluding MGNX) —-40.2%+87.2%915.8%

Competitors are the stored peer set for MGNX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue75.64M150.02M57.19M148.34M149.5M
Cost of Revenue2.65M7.38M8.22M12.3M43.18M
Gross Profit72.99M142.63M48.97M136.04M106.32M
Gross Margin96.5%95.1%85.6%91.7%71.1%
Research & Development214.58M207.03M166.58M177.19M140M
Selling, General & Admin63.01M58.95M52.19M71.05M39.16M
Operating Expenses275.79M264.05M217.22M246.62M179.16M
Depreciation & Amortization11.26M11.87M9.65M7.54M7.17M
EBITDA(190.86M)(107.89M)2.02M(57.37M)(59.61M)
EBITDA Margin-252.3%-71.9%3.5%-38.7%-39.9%
Operating Income(202.8M)(121.42M)(168.24M)(110.58M)(72.84M)
Operating Margin-268.1%-80.9%-294.2%-74.5%-48.7%
Interest Income680K1.7M9.69M9.42M3.4M
Interest Expense001.43M1.12M8.51M
Other Income / Expenses680K1.66M159.19M44.56M(2.45M)
Income Before Tax(202.12M)(119.76M)(9.06M)(66.02M)(75.29M)
Pre-Tax Margin-267.2%-79.8%-15.8%-44.5%-50.4%
Income Tax Expense000944K(672K)
Net Income(202.12M)(119.76M)(9.06M)(66.97M)(74.62M)
Net Margin-267.2%-79.8%-15.8%-45.1%-49.9%
EPS (Basic)(3.18)(1.95)(0.15)(1.07)(1.18)
EPS (Diluted)(3.18)(1.95)(0.15)(1.07)(1.18)
Weighted Avg Shares59.94M61.41M61.93M62.62M63.16M
Weighted Avg Shares (Diluted)59.94M61.43M61.93M62.62M63.16M

MacroGenics, Inc.

NASDAQ:MGNX

Intrinsic Alpha fair value

Locked

Current Price

$1.97

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.